UNICREDIT BANK/CALL/MODERNA/140/0.1/18.12.24 | Market Closed - Borsa Italiana 02:08:47 2024-07-11 pm EDT | ||
| 1.43 EUR | +21.39% |
|
| Current month | +20.29% | ||
| 1 month | -50.51% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-07-11 | 1.43 | +21.39% |
| 24-07-10 | 1.178 | +4.34% |
| 24-07-09 | 1.129 | +1.53% |
| 24-07-08 | 1.112 | -2.46% |
| 24-07-05 | 1.14 | -3.96% |
Real-time Borsa Italiana
Last update July 11, 2024 at 02:08 pm EDT
More quotesStatic data
| Product type | Warrant Plain-Vanilla |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
UniCredit
|
| UD5M7L | |
| ISIN | DE000HD5M7L6 |
| Date issued | 2024-05-15 |
| Strike | 140 $ |
| Maturity | 2024-12-18 (160 Days) |
| Parity | 10 : 1 |
| Emission price | - € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.21 € |
|---|---|
| Lowest since issue | 1.007 € |
| Spread | 0.008 € |
| Spread % | 0.57% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
117.4
USD
Average target price
145.9
USD
Spread / Average Target
+24.19%
- Stock Market
- Warrants
- UD5M7L Warrant
